Long-term clinical evaluation in patients with Parkinson's disease and early autonomic involvement

Objective: To evaluate in a prospective longitudinal study the evolution of functional disability and the response to dopaminergic therapy in PD patients with and without autonomic involvement. Methods: Sixty untreated consecutive patients with PD underwent autonomic cardiovascular function evaluation using the five autonomic tests of Ewing. An integrated index (Autonomic ScoreZAS), taking in account the results of all subtests, was calculated. Patients were treated with pergolide and bromocriptine during a 5-year follow-up until the level of functional disability was sufficient to warrant the initiation of levodopa therapy. Results: Results of autonomic testing were compared with those of a group of age-matched healthy subjects. A value of ASO2 was considered as indicative of autonomic failure. Eighteen patients with PD (35%) showed ASO2 (autonomically impaired groupZAI), the remaining 33 (65%) had AS!2 (nonautonomically impaired groupZnon-AI). During the follow-up levodopa was added to the treatment regimen of 10/18 (55%) patients in AI group, and 6/33 (18%) patients in non-AI group (p!.01). Conclusions: The increased occurrence of levodopa adjunct in autonomically impaired PD suggests that there is a more rapid deterioration of